exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088130 RNA Name: hsa-miR-3187-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 813627 End Site(bp): 813646 External Links: hsa-miR-3187-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: NA miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001867 chr9 86294689 86297981 - hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0001866 chr9 86293355 86297981 - hsa_circ_0000733 chr17 1561546 1562030 - hsa_circ_0001002 chr2 48573339 48573890 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC006064.5 chr12 6510275 6510522 + AC021078.1 chr5 149494314 149504670 - AC092295.2 chr19 36489649 36491040 + EBLN3P chr9 37079645 37090928 + LINC01184 chr5 127939152 128083172 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.